{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T07:17:43Z","timestamp":1783667863218,"version":"3.55.0"},"reference-count":81,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T00:00:00Z","timestamp":1783641600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T00:00:00Z","timestamp":1783641600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Atheroscler Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose of Review<\/jats:title>\n                    <jats:p>Summarize current literature on the use of coronary artery imaging modalities in examining the atherosclerotic and arterial inflammatory manifestations of elevated lipoprotein(a) [Lp(a)]. Evaluate the evolving role of coronary imaging in risk stratification and treatment decisions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent Findings<\/jats:title>\n                    <jats:p>While Lp(a) and calcium scoring (CAC) are independently associated with cardiovascular risk, Lp(a) is associated with CAC incidence and progression. Lp(a) is associated with greater plaque prevalence, multivessel disease, and high-risk morphologies, while also being linked to accelerated progression of mixed and lipid-rich plaque by coronary CT angiography. Intravascular imaging modalities further show associations between Lp(a) and thin-cap fibroatheroma, lipid-rich plaque, percent atheroma volume, and plaque progression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>Lp(a) is associated with non-calcified or mixed coronary plaque morphology and progression, as well as increased risk of high-risk plaque features. While additional research is needed, current literature suggests that coronary imaging may be an important tool in cardiovascular risk stratification for individuals with elevated Lp(a).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11883-026-01440-0","type":"journal-article","created":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T06:54:35Z","timestamp":1783666475000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The Evolving Role of Coronary Artery Imaging in Assessing Cardiovascular Risk from Lipoprotein(a)"],"prefix":"10.1007","volume":"28","author":[{"given":"Michael T.","family":"Savides","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harpreet S.","family":"Bhatia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inna","family":"Kuznetsova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Wilkinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,10]]},"reference":[{"issue":"39","key":"1440_CR1","doi-asserted-by":"publisher","first-page":"3925","DOI":"10.1093\/eurheartj\/ehac361","volume":"43","author":"F Kronenberg","year":"2022","unstructured":"Kronenberg F, Mora S, Stroes ESG, Ference BA, Arsenault BJ, Berglund L, et al. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. Eur Heart J. 2022;43(39):3925\u201346. https:\/\/doi.org\/10.1093\/eurheartj\/ehac361.","journal-title":"Eur Heart J"},{"issue":"43","key":"1440_CR2","doi-asserted-by":"publisher","first-page":"3492","DOI":"10.2174\/1381612829666221124110920","volume":"28","author":"S Lampsas","year":"2022","unstructured":"Lampsas S, Oikonomou E, Pantelidis P, Theofilis P, Grammatopoulos K, Marathonitis A, et al. Lipoprotein (a) Levels and Abdominal Aortic Aneurysm. A Systematic Review and Meta-analysis. Curr Pharm Des. 2022;28(43):3492\u20139. https:\/\/doi.org\/10.2174\/1381612829666221124110920.","journal-title":"Curr Pharm Des"},{"issue":"12","key":"1440_CR3","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1001\/jamacardio.2023.3548","volume":"8","author":"LF Reeskamp","year":"2023","unstructured":"Reeskamp LF, Tromp TR, Patel AP, Ibrahim S, Trinder M, Haidermota S, et al. Concordance of a High Lipoprotein(a) Concentration Among Relatives. JAMA Cardiol. 2023;8(12):1111\u20138. https:\/\/doi.org\/10.1001\/jamacardio.2023.3548.","journal-title":"JAMA Cardiol"},{"issue":"8","key":"1440_CR4","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1016\/j.cjca.2021.03.016","volume":"37","author":"GJ Pearson","year":"2021","unstructured":"Pearson GJ, Thanassoulis G, Anderson TJ, Barry AR, Couture P, Dayan N, et al. 2021 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in Adults. Can J Cardiol. 2021;37(8):1129\u201350. https:\/\/doi.org\/10.1016\/j.cjca.2021.03.016.","journal-title":"Can J Cardiol"},{"issue":"1","key":"1440_CR5","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","volume":"41","author":"F Mach","year":"2020","unstructured":"Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111\u201388. https:\/\/doi.org\/10.1093\/eurheartj\/ehz455.","journal-title":"Eur Heart J"},{"issue":"3","key":"1440_CR6","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.jacl.2019.04.010","volume":"13","author":"DP Wilson","year":"2019","unstructured":"Wilson DP, Jacobson TA, Jones PH, Koschinsky ML, McNeal CJ, Nordestgaard BG, et al. Use of Lipoprotein(a) in clinical practice: A biomarker whose time has come. A scientific statement from the National Lipid Association. J Clin Lipidol. 2019;13(3):374\u201392. https:\/\/doi.org\/10.1016\/j.jacl.2019.04.010.","journal-title":"J Clin Lipidol"},{"key":"1440_CR7","doi-asserted-by":"publisher","unstructured":"Blumenthal RS, Morris PB, Gaudino M, Johnson HM, Anderson TS, Bittner VA, et al. 2026 ACC\/AHA\/AACVPR\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2026;87(19):2624-757. https:\/\/doi.org\/10.1016\/j.jacc.2025.11.016","DOI":"10.1016\/j.jacc.2025.11.016"},{"issue":"1","key":"1440_CR8","doi-asserted-by":"publisher","first-page":"e48","DOI":"10.1161\/atv.0000000000000147","volume":"42","author":"G Reyes-Soffer","year":"2022","unstructured":"Reyes-Soffer G, Ginsberg HN, Berglund L, Duell PB, Heffron SP, Kamstrup PR, et al. Lipoprotein(a): A Genetically Determined, Causal, and Prevalent Risk Factor for Atherosclerotic Cardiovascular Disease: A Scientific Statement From the American Heart Association. Arterioscler Thromb Vasc Biol. 2022;42(1):e48\u201360. https:\/\/doi.org\/10.1161\/atv.0000000000000147.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"26","key":"1440_CR9","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.1056\/NEJMoa0902604","volume":"361","author":"R Clarke","year":"2009","unstructured":"Clarke R, Peden JF, Hopewell JC, Kyriakou T, Goel A, Heath SC, et al. Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N Engl J Med. 2009;361(26):2518\u201328. https:\/\/doi.org\/10.1056\/NEJMoa0902604.","journal-title":"N Engl J Med"},{"issue":"6","key":"1440_CR10","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1001\/archinte.168.6.598","volume":"168","author":"A Bennet","year":"2008","unstructured":"Bennet A, Di Angelantonio E, Erqou S, Eiriksdottir G, Sigurdsson G, Woodward M, et al. Lipoprotein(a) levels and risk of future coronary heart disease: large-scale prospective data. Arch Intern Med. 2008;168(6):598\u2013608. https:\/\/doi.org\/10.1001\/archinte.168.6.598.","journal-title":"Arch Intern Med"},{"issue":"7","key":"1440_CR11","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1016\/s2213-8587(17)30088-8","volume":"5","author":"D Saleheen","year":"2017","unstructured":"Saleheen D, Haycock PC, Zhao W, Rasheed A, Taleb A, Imran A, et al. Apolipoprotein(a) isoform size, lipoprotein(a) concentration, and coronary artery disease: a mendelian randomisation analysis. Lancet Diabetes Endocrinol. 2017;5(7):524\u201333. https:\/\/doi.org\/10.1016\/s2213-8587(17)30088-8.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"5","key":"1440_CR12","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1161\/01.atv.9.5.579","volume":"9","author":"M Rath","year":"1989","unstructured":"Rath M, Niendorf A, Reblin T, Dietel M, Krebber HJ, Beisiegel U. Detection and quantification of lipoprotein(a) in the arterial wall of 107 coronary bypass patients. Arteriosclerosis. 1989;9(5):579\u201392. https:\/\/doi.org\/10.1161\/01.atv.9.5.579.","journal-title":"Arteriosclerosis"},{"issue":"19","key":"1440_CR13","doi-asserted-by":"publisher","first-page":"2160","DOI":"10.1016\/j.jacc.2009.10.080","volume":"55","author":"S Erqou","year":"2010","unstructured":"Erqou S, Thompson A, Di Angelantonio E, Saleheen D, Kaptoge S, Marcovina S, et al. Apolipoprotein(a) isoforms and the risk of vascular disease: systematic review of 40 studies involving 58,000 participants. J Am Coll Cardiol. 2010;55(19):2160\u20137. https:\/\/doi.org\/10.1016\/j.jacc.2009.10.080.","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"1440_CR14","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1161\/circulationaha.124.069210","volume":"151","author":"A Greco","year":"2025","unstructured":"Greco A, Finocchiaro S, Spagnolo M, Faro DC, Mauro MS, Raffo C, et al. Lipoprotein(a) as a Pharmacological Target: Premises, Promises, and Prospects. Circulation. 2025;151(6):400\u201315. https:\/\/doi.org\/10.1161\/circulationaha.124.069210.","journal-title":"Circulation"},{"issue":"3","key":"1440_CR15","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.jacc.2021.11.015","volume":"79","author":"S Tsimikas","year":"2022","unstructured":"Tsimikas S, Narula J. Lipoprotein(a) and CT Angiography: Novel Insights Into High-Risk Plaque Progression. J Am Coll Cardiol. 2022;79(3):234\u20137. https:\/\/doi.org\/10.1016\/j.jacc.2021.11.015.","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"1440_CR16","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1097\/mol.0000000000001000","volume":"36","author":"JM Assini","year":"2025","unstructured":"Assini JM, Boffa MB, Koschinsky ML. The complex pro-atherosclerotic role of lipoprotein(a): a multiplicity of cellular targets. Curr Opin Lipidol. 2025;36(5):268\u201375. https:\/\/doi.org\/10.1097\/mol.0000000000001000.","journal-title":"Curr Opin Lipidol"},{"issue":"7","key":"1440_CR17","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1001\/jamacardio.2022.0987","volume":"7","author":"F Duarte Lau","year":"2022","unstructured":"Duarte Lau F, Giugliano RP. Lipoprotein(a) and its Significance in Cardiovascular Disease: A Review. JAMA Cardiol. 2022;7(7):760\u20139. https:\/\/doi.org\/10.1001\/jamacardio.2022.0987.","journal-title":"JAMA Cardiol"},{"issue":"1","key":"1440_CR18","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1007\/s11886-025-02210-1","volume":"27","author":"S Palanisamy","year":"2025","unstructured":"Palanisamy S, Burka S, Blaha MJ. Coronary Artery Calcium Scoring in the Context of Widespread Lipoprotein(a) Testing: Clinical Considerations and Implications for Lipid-Lowering Therapies. Curr Cardiol Rep. 2025;27(1):52. https:\/\/doi.org\/10.1007\/s11886-025-02210-1.","journal-title":"Curr Cardiol Rep"},{"issue":"9","key":"1440_CR19","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1093\/eurjpc\/zwaf196","volume":"32","author":"AC Razavi","year":"2025","unstructured":"Razavi AC, Blaha MJ, Bhatia HS. Inconsistent association between lipoprotein(a) and coronary artery calcium. Eur J Prev Cardiol. 2025;32(9):756\u20137. https:\/\/doi.org\/10.1093\/eurjpc\/zwaf196.","journal-title":"Eur J Prev Cardiol"},{"issue":"4","key":"1440_CR20","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1161\/circulationaha.124.069556","volume":"151","author":"HS Bhatia","year":"2025","unstructured":"Bhatia HS, Wandel S, Willeit P, Lesogor A, Bailey K, Ridker PM, et al. Independence of Lipoprotein(a) and Low-Density Lipoprotein Cholesterol-Mediated Cardiovascular Risk: A Participant-Level Meta-Analysis. Circulation. 2025;151(4):312\u201321. https:\/\/doi.org\/10.1161\/circulationaha.124.069556.","journal-title":"Circulation"},{"issue":"1","key":"1440_CR21","doi-asserted-by":"publisher","first-page":"e18","DOI":"10.1097\/fjc.0000000000001160","volume":"79","author":"H Melita","year":"2022","unstructured":"Melita H, Manolis AA, Manolis TA, Manolis AS. Lipoprotein(a) and Cardiovascular Disease: A Missing Link for Premature Atherosclerotic Heart Disease and\/or Residual Risk. J Cardiovasc Pharmacol. 2022;79(1):e18\u201335. https:\/\/doi.org\/10.1097\/fjc.0000000000001160.","journal-title":"J Cardiovasc Pharmacol"},{"issue":"2","key":"1440_CR22","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1210\/clinem\/dgab734","volume":"107","author":"N Strandkjaer","year":"2022","unstructured":"Strandkjaer N, Hansen MK, Nielsen ST, Frikke-Schmidt R, Tybjaerg-Hansen A, Nordestgaard BG, et al. Lipoprotein(a) Levels at Birth and in Early Childhood: The COMPARE Study. J Clin Endocrinol Metab. 2022;107(2):324\u201335. https:\/\/doi.org\/10.1210\/clinem\/dgab734.","journal-title":"J Clin Endocrinol Metab"},{"key":"1440_CR23","doi-asserted-by":"publisher","unstructured":"Nasoufidou A, Glava A, Mavridou M, Stachteas P, Karagiannidis E, Patoulias D, et al. Age-Dependent Clinical Relevance of Lipoprotein(a): A Comprehensive Review from Childhood to Adulthood. J Clin Med. 2025;14(17):6018. https:\/\/doi.org\/10.3390\/jcm14176018","DOI":"10.3390\/jcm14176018"},{"issue":"10","key":"1440_CR24","doi-asserted-by":"publisher","first-page":"e177","DOI":"10.1016\/j.jacc.2019.03.010","volume":"74","author":"DK Arnett","year":"2019","unstructured":"Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, et al. 2019 ACC\/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019;74(10):e177\u2013232. https:\/\/doi.org\/10.1016\/j.jacc.2019.03.010.","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"1440_CR25","doi-asserted-by":"publisher","first-page":"445","DOI":"10.3349\/ymj.2003.44.3.445","volume":"44","author":"SK Ryu","year":"2003","unstructured":"Ryu SK, Hong BK, Kwon HM, Kim DS, Chung WJ, Park BE, et al. Age-related contribution of Lp(a) with coronary artery calcification in patients with acute coronary syndrome: a potential role of metabolic disorder in calcified plaque. Yonsei Med J. 2003;44(3):445\u201353. https:\/\/doi.org\/10.3349\/ymj.2003.44.3.445.","journal-title":"Yonsei Med J"},{"issue":"10","key":"1440_CR26","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.4065\/79.10.1258","volume":"79","author":"IJ Kullo","year":"2004","unstructured":"Kullo IJ, Bailey KR, Bielak LF, Sheedy PF 2nd, Klee GG, Kardia SL et al. Lack of association between lipoprotein(a) and coronary artery calcification in the Genetic Epidemiology Network of Arteriopathy (GENOA) study. Mayo Clin Proc. 2004;79(10):1258-63. https:\/\/doi.org\/10.4065\/79.10.1258","journal-title":"Mayo Clin Proc"},{"issue":"2","key":"1440_CR27","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/s0735-1097(99)00555-0","volume":"35","author":"M Nishino","year":"2000","unstructured":"Nishino M, Malloy MJ, Naya-Vigne J, Russell J, Kane JP, Redberg RF. Lack of association of lipoprotein(a) levels with coronary calcium deposits in asymptomatic postmenopausal women. J Am Coll Cardiol. 2000;35(2):314\u201320. https:\/\/doi.org\/10.1016\/s0735-1097(99)00555-0.","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"1440_CR28","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.jcct.2020.06.002","volume":"15","author":"PK Garg","year":"2021","unstructured":"Garg PK, Guan W, Karger AB, Steffen BT, Budoff M, Tsai MY. Lipoprotein (a) and risk for calcification of the coronary arteries, mitral valve, and thoracic aorta: The Multi-Ethnic Study of Atherosclerosis. J Cardiovasc Comput Tomogr. 2021;15(2):154\u201360. https:\/\/doi.org\/10.1016\/j.jcct.2020.06.002.","journal-title":"J Cardiovasc Comput Tomogr"},{"key":"1440_CR29","doi-asserted-by":"publisher","first-page":"154706","DOI":"10.1016\/j.metabol.2021.154706","volume":"116","author":"KL Ong","year":"2021","unstructured":"Ong KL, McClelland RL, Allison MA, Cushman M, Garg PK, Tsai MY, et al. Lipoprotein (a) and coronary artery calcification: prospective study assessing interactions with other risk factors. Metabolism. 2021;116:154706. https:\/\/doi.org\/10.1016\/j.metabol.2021.154706.","journal-title":"Metabolism"},{"key":"1440_CR30","doi-asserted-by":"publisher","first-page":"100453","DOI":"10.1016\/j.ajpc.2022.100453","volume":"13","author":"H Shah","year":"2023","unstructured":"Shah H, Garacci E, Behuria S, Cainzos-Achirica M, Kandula NR, Kanaya AM, et al. Cardiovascular risk-enhancing factors and coronary artery calcium in South Asian American adults: The MASALA study. Am J Prev Cardiol. 2023;13:100453. https:\/\/doi.org\/10.1016\/j.ajpc.2022.100453.","journal-title":"Am J Prev Cardiol"},{"key":"1440_CR31","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.atherosclerosis.2022.05.006","volume":"353","author":"HS Bhatia","year":"2022","unstructured":"Bhatia HS, Lin F, Thomas IC, Denenberg J, Kandula NR, Budoff MJ, et al. Coronary artery calcium incidence and changes using direct plaque measurements: The MASALA study. Atherosclerosis. 2022;353:41\u20136. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2022.05.006.","journal-title":"Atherosclerosis"},{"issue":"10","key":"1440_CR32","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1016\/j.jcmg.2024.05.023","volume":"17","author":"ND Wong","year":"2024","unstructured":"Wong ND, Fan W, Hu X, Ballantyne C, Hoogeveen R, Tsai MY, et al. Lipoprotein(a) and Progression of Coronary Artery Calcification in a Pooled U.S. Cohort. JACC Cardiovasc Imaging. 2024;17(10):1265\u20137. https:\/\/doi.org\/10.1016\/j.jcmg.2024.05.023.","journal-title":"JACC Cardiovasc Imaging"},{"issue":"4","key":"1440_CR33","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1016\/j.jacl.2023.06.002","volume":"17","author":"CL Jackson","year":"2023","unstructured":"Jackson CL, Garg PK, Guan W, Tsai MY, Criqui MH, Tsimikas S, et al. Lipoprotein(a) and coronary artery calcium in comparison with other lipid biomarkers: The multi-ethnic study of atherosclerosis. J Clin Lipidol. 2023;17(4):538\u201348. https:\/\/doi.org\/10.1016\/j.jacl.2023.06.002.","journal-title":"J Clin Lipidol"},{"issue":"11","key":"1440_CR34","doi-asserted-by":"publisher","first-page":"e024870","DOI":"10.1161\/jaha.121.024870","volume":"11","author":"OH Obisesan","year":"2022","unstructured":"Obisesan OH, Kou M, Wang FM, Boakye E, Honda Y, Uddin SMI, et al. Lipoprotein(a) and Subclinical Vascular and Valvular Calcification on Cardiac Computed Tomography: The Atherosclerosis Risk in Communities Study. J Am Heart Assoc. 2022;11(11):e024870. https:\/\/doi.org\/10.1161\/jaha.121.024870.","journal-title":"J Am Heart Assoc"},{"issue":"3","key":"1440_CR35","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/j.jacl.2018.02.007","volume":"12","author":"SL Verweij","year":"2018","unstructured":"Verweij SL, de Ronde MWJ, Verbeek R, Boekholdt SM, Planken RN, Stroes ESG, et al. Elevated lipoprotein(a) levels are associated with coronary artery calcium scores in asymptomatic individuals with a family history of premature atherosclerotic cardiovascular disease. J Clin Lipidol. 2018;12(3):597\u2013e6031. https:\/\/doi.org\/10.1016\/j.jacl.2018.02.007.","journal-title":"J Clin Lipidol"},{"issue":"11","key":"1440_CR36","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1016\/j.numecd.2023.07.015","volume":"33","author":"F Vazirian","year":"2023","unstructured":"Vazirian F, Sadeghi M, Kelesidis T, Budoff MJ, Zandi Z, Samadi S, et al. Predictive value of lipoprotein(a) in coronary artery calcification among asymptomatic cardiovascular disease subjects: A systematic review and meta-analysis. Nutr Metab Cardiovasc Dis. 2023;33(11):2055\u201366. https:\/\/doi.org\/10.1016\/j.numecd.2023.07.015.","journal-title":"Nutr Metab Cardiovasc Dis"},{"issue":"6","key":"1440_CR37","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1093\/eurjpc\/zwae043","volume":"31","author":"FV Martignoni","year":"2024","unstructured":"Martignoni FV, Rl J\u00fanior JE, Marques IR, Gomes C, Moreira VCS, de Souza IAF, et al. The association of lipoprotein(a) and coronary artery calcium in asymptomatic patients: a systematic review and meta-analysis. Eur J Prev Cardiol. 2024;31(6):732\u201341. https:\/\/doi.org\/10.1093\/eurjpc\/zwae043.","journal-title":"Eur J Prev Cardiol"},{"key":"1440_CR38","doi-asserted-by":"publisher","first-page":"117405","DOI":"10.1016\/j.atherosclerosis.2023.117405","volume":"388","author":"Y Qiu","year":"2024","unstructured":"Qiu Y, Hao W, Guo Y, Guo Q, Zhang Y, Liu X, et al. The association of lipoprotein (a) with coronary artery calcification: A systematic review and meta-analysis. Atherosclerosis. 2024;388:117405. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2023.117405.","journal-title":"Atherosclerosis"},{"issue":"9","key":"1440_CR39","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1093\/eurjpc\/zwaf088","volume":"32","author":"DE Sung","year":"2025","unstructured":"Sung DE, Rhee EJ, Lee JY, Lee MY, Sung KC. Elevated lipoprotein(a) is not linked to coronary artery calcification incidence or progression. Eur J Prev Cardiol. 2025;32(9):746\u201355. https:\/\/doi.org\/10.1093\/eurjpc\/zwaf088.","journal-title":"Eur J Prev Cardiol"},{"issue":"8","key":"1440_CR40","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/j.jacc.2021.11.058","volume":"79","author":"A Mehta","year":"2022","unstructured":"Mehta A, Vasquez N, Ayers CR, Patel J, Hooda A, Khera A, et al. Independent Association of Lipoprotein(a) and Coronary Artery Calcification With Atherosclerotic Cardiovascular Risk. J Am Coll Cardiol. 2022;79(8):757\u201368. https:\/\/doi.org\/10.1016\/j.jacc.2021.11.058.","journal-title":"J Am Coll Cardiol"},{"key":"1440_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2026.02.5067","author":"HS Bhatia","year":"2026","unstructured":"Bhatia HS, Fan Y, Dharmavaram G, Razavi AC, Tsai MY, Ramsis M, et al. Use of Coronary Artery Calcium Scoring in Individuals With Elevated Lipoprotein(a): A Multicohort Study. J Am Coll Cardiol. 2026. https:\/\/doi.org\/10.1016\/j.jacc.2026.02.5067.","journal-title":"J Am Coll Cardiol"},{"key":"1440_CR42","unstructured":"Annink ME. Heart CT imaging to detect early coronary artery disease in first-degree relatives with high or low lipoprotein(a) identified through family screening (IMAGE-LPA ). ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). 2025. Identifier: NCT06995183. https:\/\/clinicaltrials.gov\/study\/NCT06995183"},{"issue":"21","key":"1440_CR43","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.1016\/j.jacc.2008.07.031","volume":"52","author":"MJ Budoff","year":"2008","unstructured":"Budoff MJ, Dowe D, Jollis JG, Gitter M, Sutherland J, Halamert E, et al. Diagnostic performance of 64-multidetector row coronary computed tomographic angiography for evaluation of coronary artery stenosis in individuals without known coronary artery disease: results from the prospective multicenter ACCURACY (Assessment by Coronary Computed Tomographic Angiography of Individuals Undergoing Invasive Coronary Angiography) trial. J Am Coll Cardiol. 2008;52(21):1724\u201332. https:\/\/doi.org\/10.1016\/j.jacc.2008.07.031.","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"1440_CR44","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1161\/01.cir.74.4.758","volume":"74","author":"GH Dahlen","year":"1986","unstructured":"Dahlen GH, Guyton JR, Attar M, Farmer JA, Kautz JA, Gotto AM. Jr. Association of levels of lipoprotein Lp(a), plasma lipids, and other lipoproteins with coronary artery disease documented by angiography. Circulation. 1986;74(4):758\u201365. https:\/\/doi.org\/10.1161\/01.cir.74.4.758.","journal-title":"Circulation"},{"issue":"7","key":"1440_CR45","doi-asserted-by":"publisher","first-page":"e016152","DOI":"10.1161\/circimaging.123.016152","volume":"17","author":"R Mszar","year":"2024","unstructured":"Mszar R, Cainzos-Achirica M, Valero-Elizondo J, Lahan S, Al-Kindi SG, Quispe R, et al. Lipoprotein(a) and Coronary Plaque in Asymptomatic Individuals: The Miami Heart Study at Baptist Health South Florida. Circ Cardiovasc Imaging. 2024;17(7):e016152. https:\/\/doi.org\/10.1161\/circimaging.123.016152.","journal-title":"Circ Cardiovasc Imaging"},{"key":"1440_CR46","doi-asserted-by":"publisher","DOI":"10.1093\/eurjpc\/zwaf323","author":"S Fathieh","year":"2025","unstructured":"Fathieh S, Tang O, Gray MP, Zanchin C, Vernon ST, Genetzakis E, et al. Evaluating the Role of Lipoprotein(a) in Enhancing Risk Stratification for the Presence and Extent of Subclinical Coronary Artery Disease Burden - A BioHEART-CT Study. Eur J Prev Cardiol. 2025. https:\/\/doi.org\/10.1093\/eurjpc\/zwaf323.","journal-title":"Eur J Prev Cardiol"},{"key":"1440_CR47","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.atherosclerosis.2021.09.027","volume":"349","author":"H Lee","year":"2022","unstructured":"Lee H, Park KS, Jeon YJ, Park EJ, Park S, Ann SH, et al. Lipoprotein(a) and subclinical coronary atherosclerosis in asymptomatic individuals. Atherosclerosis. 2022;349:190\u20135. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2021.09.027.","journal-title":"Atherosclerosis"},{"issue":"12","key":"1440_CR48","doi-asserted-by":"publisher","first-page":"e014611","DOI":"10.1161\/circimaging.122.014611","volume":"15","author":"N Dai","year":"2022","unstructured":"Dai N, Chen Z, Zhou F, Zhou Y, Hu N, Duan S, et al. Association of Lipoprotein (a) With Coronary-Computed Tomography Angiography-Assessed High-Risk Coronary Disease Attributes and Cardiovascular Outcomes. Circ Cardiovasc Imaging. 2022;15(12):e014611. https:\/\/doi.org\/10.1161\/circimaging.122.014611.","journal-title":"Circ Cardiovasc Imaging"},{"issue":"7","key":"1440_CR49","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1093\/eurjpc\/zwae007","volume":"31","author":"DM Leistner","year":"2024","unstructured":"Leistner DM, Laguna-Fernandez A, Haghikia A, Abdelwahed YS, Schatz AS, Erbay A, et al. Impact of elevated lipoprotein(a) on coronary artery disease phenotype and severity. Eur J Prev Cardiol. 2024;31(7):856\u201365. https:\/\/doi.org\/10.1093\/eurjpc\/zwae007.","journal-title":"Eur J Prev Cardiol"},{"issue":"2","key":"1440_CR50","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.jcct.2020.11.002","volume":"15","author":"LJ Shaw","year":"2021","unstructured":"Shaw LJ, Blankstein R, Bax JJ, Ferencik M, Bittencourt MS, Min JK, et al. Society of Cardiovascular Computed Tomography \/ North American Society of Cardiovascular Imaging - Expert Consensus Document on Coronary CT Imaging of Atherosclerotic Plaque. J Cardiovasc Comput Tomogr. 2021;15(2):93\u2013109. https:\/\/doi.org\/10.1016\/j.jcct.2020.11.002.","journal-title":"J Cardiovasc Comput Tomogr"},{"key":"1440_CR51","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.amjcard.2024.09.006","volume":"231","author":"T O\u2019Toole","year":"2024","unstructured":"O\u2019Toole T, Shah NP, Giamberardino SN, Kwee LC, Voora D, McGarrah RW, et al. Association Between Lipoprotein(a) and Obstructive Coronary Artery Disease and High-Risk Plaque: Insights From the PROMISE Trial. Am J Cardiol. 2024;231:40\u20137. https:\/\/doi.org\/10.1016\/j.amjcard.2024.09.006.","journal-title":"Am J Cardiol"},{"key":"1440_CR52","doi-asserted-by":"publisher","unstructured":"Bhatia HS, Wilkinson MJ. Lipoprotein(a): Evidence for Role as a Causal Risk Factor in Cardiovascular Disease and Emerging Therapies. J Clin Med. 2022;11(20):6040. https:\/\/doi.org\/10.3390\/jcm11206040","DOI":"10.3390\/jcm11206040"},{"key":"1440_CR53","doi-asserted-by":"publisher","unstructured":"Pugliese L, Ricci F, Sica G, Scaglione M, Masala S. Non-contrast and contrast-enhanced cardiac computed tomography imaging in the diagnostic and prognostic evaluation of coronary artery disease. Diagnostics (Basel). 2023;13(12):2074. https:\/\/doi.org\/10.3390\/diagnostics13122074","DOI":"10.3390\/diagnostics13122074"},{"issue":"3","key":"1440_CR54","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.jacc.2021.10.044","volume":"79","author":"Y Kaiser","year":"2022","unstructured":"Kaiser Y, Daghem M, Tzolos E, Meah MN, Doris MK, Moss AJ, et al. Association of Lipoprotein(a) With Atherosclerotic Plaque Progression. J Am Coll Cardiol. 2022;79(3):223\u201333. https:\/\/doi.org\/10.1016\/j.jacc.2021.10.044.","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"1440_CR55","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1001\/jamacardio.2024.1874","volume":"9","author":"NS Nurmohamed","year":"2024","unstructured":"Nurmohamed NS, Gaillard EL, Malkasian S, de Groot RJ, Ibrahim S, Bom MJ, et al. Lipoprotein(a) and Long-Term Plaque Progression, Low-Density Plaque, and Pericoronary Inflammation. JAMA Cardiol. 2024;9(9):826\u201334. https:\/\/doi.org\/10.1001\/jamacardio.2024.1874.","journal-title":"JAMA Cardiol"},{"issue":"3","key":"1440_CR56","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1007\/s00330-024-11313-2","volume":"35","author":"Z Lan","year":"2025","unstructured":"Lan Z, Ding X, Yang W, Yuan J, Yu Y, Yu L, et al. Impact of lipoprotein (a) on coronary atherosclerosis and plaque progression in patients with type 2 diabetes mellitus. Eur Radiol. 2025;35(3):1533\u201342. https:\/\/doi.org\/10.1007\/s00330-024-11313-2.","journal-title":"Eur Radiol"},{"issue":"11","key":"1440_CR57","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1002\/clc.23718","volume":"44","author":"X Shui","year":"2021","unstructured":"Shui X, Wen Z, Chen Z, Xie X, Wu Y, Zheng B, et al. Elevated serum lipoprotein(a) is significantly associated with angiographic progression of coronary artery disease. Clin Cardiol. 2021;44(11):1551\u20139. https:\/\/doi.org\/10.1002\/clc.23718.","journal-title":"Clin Cardiol"},{"issue":"3","key":"1440_CR58","doi-asserted-by":"publisher","first-page":"100597","DOI":"10.1016\/j.cpcardiol.2020.100597","volume":"46","author":"SM Hasan","year":"2021","unstructured":"Hasan SM, Faluk M, Patel JD, Abdelmaseih R, Patel J. Use of Optical Coherence Tomography in Coronary Artery Disease: Review Article. Curr Probl Cardiol. 2021;46(3):100597. https:\/\/doi.org\/10.1016\/j.cpcardiol.2020.100597.","journal-title":"Curr Probl Cardiol"},{"key":"1440_CR59","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.atherosclerosis.2016.01.020","volume":"246","author":"G Niccoli","year":"2016","unstructured":"Niccoli G, Cin D, Scalone G, Panebianco M, Abbolito S, Cosentino N, et al. Lipoprotein (a) is related to coronary atherosclerotic burden and a vulnerable plaque phenotype in angiographically obstructive coronary artery disease. Atherosclerosis. 2016;246:214\u201320. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2016.01.020.","journal-title":"Atherosclerosis"},{"key":"1440_CR60","doi-asserted-by":"publisher","first-page":"100382","DOI":"10.1016\/j.ijcha.2019.100382","volume":"24","author":"Y Muramatsu","year":"2019","unstructured":"Muramatsu Y, Minami Y, Kato A, Katsura A, Sato T, Kakizaki R, et al. Lipoprotein (a) level is associated with plaque vulnerability in patients with coronary artery disease: An optical coherence tomography study. Int J Cardiol Heart Vasc. 2019;24:100382. https:\/\/doi.org\/10.1016\/j.ijcha.2019.100382.","journal-title":"Int J Cardiol Heart Vasc"},{"issue":"7","key":"1440_CR61","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1016\/j.jcmg.2022.03.002","volume":"15","author":"SJ Nicholls","year":"2022","unstructured":"Nicholls SJ, Kataoka Y, Nissen SE, Prati F, Windecker S, Puri R, et al. Effect of Evolocumab on Coronary Plaque Phenotype and Burden in Statin-Treated Patients Following Myocardial Infarction. JACC Cardiovasc Imaging. 2022;15(7):1308\u201321. https:\/\/doi.org\/10.1016\/j.jcmg.2022.03.002.","journal-title":"JACC Cardiovasc Imaging"},{"key":"1440_CR62","doi-asserted-by":"publisher","DOI":"10.1093\/eurjpc\/zwaf211","author":"G Di Giovanni","year":"2025","unstructured":"Di Giovanni G, Fujino M, Kataoka Y, Butters J, Hucko T, Puri R, et al. Impact of evolocumab on plaque phenotypic changes in patients with acute coronary syndrome and elevated lipoprotein(a) levels: a HUYGENS secondary analysis. Eur J Prev Cardiol. 2025. https:\/\/doi.org\/10.1093\/eurjpc\/zwaf211.","journal-title":"Eur J Prev Cardiol"},{"issue":"10","key":"1440_CR63","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1016\/j.jcmg.2022.04.026","volume":"15","author":"GS Mintz","year":"2022","unstructured":"Mintz GS, Matsumura M, Ali Z, Maehara A. Clinical Utility of Intravascular Imaging: Past, Present, and Future. JACC Cardiovasc Imaging. 2022;15(10):1799\u2013820. https:\/\/doi.org\/10.1016\/j.jcmg.2022.04.026.","journal-title":"JACC Cardiovasc Imaging"},{"issue":"4","key":"1440_CR64","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1161\/01.cir.103.4.604","volume":"103","author":"SE Nissen","year":"2001","unstructured":"Nissen SE, Yock P. Intravascular ultrasound: novel pathophysiological insights and current clinical applications. Circulation. 2001;103(4):604\u201316. https:\/\/doi.org\/10.1161\/01.cir.103.4.604.","journal-title":"Circulation"},{"issue":"13","key":"1440_CR65","doi-asserted-by":"publisher","first-page":"e771","DOI":"10.1161\/cir.0000000000001309","volume":"151","author":"SV Rao","year":"2025","unstructured":"Rao SV, O\u2019Donoghue ML, Ruel M, Rab T, Tamis-Holland JE, Alexander JH, et al. 2025 ACC\/AHA\/ACEP\/NAEMSP\/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2025;151(13):e771\u2013862. https:\/\/doi.org\/10.1161\/cir.0000000000001309.","journal-title":"Circulation"},{"issue":"3","key":"1440_CR66","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.jacc.2006.03.047","volume":"48","author":"M Hartmann","year":"2006","unstructured":"Hartmann M, von Birgelen C, Mintz GS, Stoel MG, Eggebrecht H, Wieneke H, et al. Relation between lipoprotein(a) and fibrinogen and serial intravascular ultrasound plaque progression in left main coronary arteries. J Am Coll Cardiol. 2006;48(3):446\u201352. https:\/\/doi.org\/10.1016\/j.jacc.2006.03.047.","journal-title":"J Am Coll Cardiol"},{"issue":"23","key":"1440_CR67","doi-asserted-by":"publisher","first-page":"e018023","DOI":"10.1161\/jaha.120.018023","volume":"9","author":"CP Huded","year":"2020","unstructured":"Huded CP, Shah NP, Puri R, Nicholls SJ, Wolski K, Nissen SE, et al. Association of Serum Lipoprotein (a) Levels and Coronary Atheroma Volume by Intravascular Ultrasound. J Am Heart Assoc. 2020;9(23):e018023. https:\/\/doi.org\/10.1161\/jaha.120.018023.","journal-title":"J Am Heart Assoc"},{"issue":"18","key":"1440_CR68","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1001\/jama.2022.5218","volume":"327","author":"L R\u00e4ber","year":"2022","unstructured":"R\u00e4ber L, Ueki Y, Otsuka T, Losdat S, H\u00e4ner JD, Lonborg J, et al. Effect of Alirocumab Added to High-Intensity Statin Therapy on Coronary Atherosclerosis in Patients With Acute Myocardial Infarction: The PACMAN-AMI Randomized Clinical Trial. JAMA. 2022;327(18):1771\u201381. https:\/\/doi.org\/10.1001\/jama.2022.5218.","journal-title":"JAMA"},{"issue":"11","key":"1440_CR69","doi-asserted-by":"publisher","first-page":"e016683","DOI":"10.1161\/circimaging.124.016683","volume":"17","author":"KC Koskinas","year":"2024","unstructured":"Koskinas KC, H\u00e4ner J, Ueki Y, Otsuka T, Lonborg J, Shibutani H, et al. Association of Lipoprotein(a) With Changes in Coronary Atherosclerosis in Patients Treated With Alirocumab. Circ Cardiovasc Imaging. 2024;17(11):e016683. https:\/\/doi.org\/10.1161\/circimaging.124.016683.","journal-title":"Circ Cardiovasc Imaging"},{"key":"1440_CR70","doi-asserted-by":"publisher","first-page":"175394472413033","DOI":"10.1177\/17539447241303399","volume":"18","author":"J Xia","year":"2024","unstructured":"Xia J, Bachour K, Suleiman AM, Roberts JS, Sayed S, Cho GW. Enhancing coronary artery plaque analysis via artificial intelligence-driven cardiovascular computed tomography. Ther Adv Cardiovasc Dis. 2024;18:17539447241303399. https:\/\/doi.org\/10.1177\/17539447241303399.","journal-title":"Ther Adv Cardiovasc Dis"},{"issue":"33","key":"1440_CR71","doi-asserted-by":"publisher","first-page":"2775","DOI":"10.1093\/eurheartj\/ehy862","volume":"40","author":"LCA Stiekema","year":"2019","unstructured":"Stiekema LCA, Stroes ESG, Verweij SL, Kassahun H, Chen L, Wasserman SM, et al. Persistent arterial wall inflammation in patients with elevated lipoprotein(a) despite strong low-density lipoprotein cholesterol reduction by proprotein convertase subtilisin\/kexin type 9 antibody treatment. Eur Heart J. 2019;40(33):2775\u201381. https:\/\/doi.org\/10.1093\/eurheartj\/ehy862.","journal-title":"Eur Heart J"},{"issue":"11","key":"1440_CR72","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1016\/j.jacc.2021.12.032","volume":"79","author":"C Yeang","year":"2022","unstructured":"Yeang C, Karwatowska-Prokopczuk E, Su F, Dinh B, Xia S, Witztum JL, et al. Effect of Pelacarsen on Lipoprotein(a) Cholesterol and Corrected Low-Density Lipoprotein Cholesterol. J Am Coll Cardiol. 2022;79(11):1035\u201346. https:\/\/doi.org\/10.1016\/j.jacc.2021.12.032.","journal-title":"J Am Coll Cardiol"},{"issue":"20","key":"1440_CR73","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1056\/NEJMoa2211023","volume":"387","author":"ML O\u2019Donoghue","year":"2022","unstructured":"O\u2019Donoghue ML, Rosenson RS, Gencer B, L\u00f3pez JAG, Lepor NE, Baum SJ, et al. Small Interfering RNA to Reduce Lipoprotein(a) in Cardiovascular Disease. N Engl J Med. 2022;387(20):1855\u201364. https:\/\/doi.org\/10.1056\/NEJMoa2211023.","journal-title":"N Engl J Med"},{"key":"1440_CR74","unstructured":"Novartis Pharmaceuticals. A multicenter trial assessing the impact of lipoprotein(a) lowering with pelacarsen (TQJ230) on the progression of calcific aortic valve stenosis. ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). 2026. Identifier: NCT05646381."},{"key":"1440_CR75","unstructured":"Amgen. Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction (OCEAN(a)) - Outcomes Trial. ClinicalTrials.gov2026."},{"issue":"4","key":"1440_CR76","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1016\/j.amepre.2024.06.008","volume":"67","author":"R Anokye","year":"2024","unstructured":"Anokye R, Via JD, Dimmock J, Jackson B, Schultz C, Sch\u00e6ffer M, et al. Impact of Cardiovascular Imaging Results on Medication Use and Adherence: A Systematic Review and Meta-Analysis. Am J Prev Med. 2024;67(4):606\u201317. https:\/\/doi.org\/10.1016\/j.amepre.2024.06.008.","journal-title":"Am J Prev Med"},{"key":"1440_CR77","doi-asserted-by":"publisher","unstructured":"Anokye R, Jackson B, Dimmock J, Dickson JM, Kennedy MA, Schultz CJ, et al. Impact of vascular screening interventions on perceived threat, efficacy beliefs and behavioural intentions: a systematic narrative review. Health Promot Int. 2023;38(3):daad040. https:\/\/doi.org\/10.1093\/heapro\/daad040","DOI":"10.1093\/heapro\/daad040"},{"key":"1440_CR78","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcmg.2025.12.008","author":"AC Razavi","year":"2026","unstructured":"Razavi AC, Dzaye O, Bhatia HS, Vaccarino V, Mehta A, Rotter JI, et al. Modeling Benefit of Aspirin According to Lp(a) and Coronary Artery Calcium: MESA. JACC Cardiovasc Imaging. 2026. https:\/\/doi.org\/10.1016\/j.jcmg.2025.12.008.","journal-title":"JACC Cardiovasc Imaging"},{"issue":"19","key":"1440_CR79","doi-asserted-by":"publisher","first-page":"e391","DOI":"10.1161\/cir.0000000000001382","volume":"152","author":"R Foraker","year":"2025","unstructured":"Foraker R, Sperling L, Bratzke L, Budoff M, Leppert M, Razavi AC, et al. Opportunistic Detection of Coronary Artery Calcium on Noncardiac Chest Computed Tomography: An Emerging Tool for Cardiovascular Disease Prevention: A Scientific Statement From the American Heart Association. Circulation. 2025;152(19):e391\u2013401. https:\/\/doi.org\/10.1161\/cir.0000000000001382.","journal-title":"Circulation"},{"key":"1440_CR80","doi-asserted-by":"publisher","first-page":"120479","DOI":"10.1016\/j.atherosclerosis.2025.120479","volume":"409","author":"F Mach","year":"2025","unstructured":"Mach F, Koskinas KC, van Roeters JE, Tokg\u00f6zo\u011flu L, Badimon L, Baigent C, et al. 2025 Focused Update of the 2019 ESC\/EAS Guidelines for the management of dyslipidaemias. Atherosclerosis. 2025;409:120479. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2025.120479.","journal-title":"Atherosclerosis"},{"issue":"3","key":"1440_CR81","doi-asserted-by":"publisher","first-page":"e308","DOI":"10.1016\/j.jacl.2024.03.001","volume":"18","author":"ML Koschinsky","year":"2024","unstructured":"Koschinsky ML, Bajaj A, Boffa MB, Dixon DL, Ferdinand KC, Gidding SS, et al. A focused update to the 2019 NLA scientific statement on use of lipoprotein(a) in clinical practice. J Clin Lipidol. 2024;18(3):e308\u201319. https:\/\/doi.org\/10.1016\/j.jacl.2024.03.001.","journal-title":"J Clin Lipidol"}],"container-title":["Current Atherosclerosis Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-026-01440-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11883-026-01440-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-026-01440-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T06:54:36Z","timestamp":1783666476000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11883-026-01440-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,10]]},"references-count":81,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1440"],"URL":"https:\/\/doi.org\/10.1007\/s11883-026-01440-0","relation":{},"ISSN":["1534-6242"],"issn-type":[{"value":"1534-6242","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,10]]},"assertion":[{"value":"23 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"N\/A.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}},{"value":"Funding: HSB and MJW are supported by the BEACON Lp(a) Research Center at UC San Diego. HSB is supported by National Institutes of Health, Grant 1K08HL166962. MJW is supported by the National Institutes of Health grants 1R01DK118278-01 and R01DK139356 and by a grant from the Larry L. Hillblom Foundation. The content of this article is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.Conflict of Interest: HSB is a consultant \/ advisor for Kaneka, Novartis, Arrowhead, Merck, Bayer, Abbott and NewAmsterdam. MJW is a consultant to Amarin, Regeneron, Kaneka, Ionis, and NewAmsterdam; reports advisory board fees from Lilly, Novartis, Regeneron, Ionis, Arrowhead, and NewAmsterdam; received grant support from Amgen and Esperion (investigator-initiated studies) and support through an institutional consulting agreement with Novartis paid to his institution for advising on research; and has contracted research grants to his institution with Amgen, Novartis, Ionis, Lilly, Silence, and Mineralys. MTS and IK have no relevant disclosures.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"69"}}